#ECTRIMS2018 ā Additional Analysis on Ozanimod Demonstrates Its Potential to Treat Relapsing MS
Additional analysis of clinical data from Celgeneās investigational agent ozanimod continues to demonstrate its potential to benefit patients with relapsing multiple sclerosis (MS). Findings from the Phase 3 SUNBEAM and RADIANCE Part B trials were discussed at…